Literature DB >> 7866123

Relative mortality from overdose of antidepressants.

J A Henry1, C A Alexander, E K Sener.   

Abstract

OBJECTIVE: To compare the fatal toxicities of antidepressant drugs in 1987-92.
DESIGN: Retrospective epidemiological review of prescription data of the Department of Health, Scottish Office Home and Health Department, and Welsh Health Common Services Authority (excluding data from most private general practices and most hospitals), and mortality data from the Office of Population Censuses and Surveys and General Register Office in Scotland.
SETTING: General practice, England, Scotland, and Wales. MAIN OUTCOME MEASURES: Deaths per million prescriptions and deaths per defined daily dose.
RESULTS: 81.6% (1310/1606) of deaths from antidepressant overdose were due to two drugs, amitriptyline and dothiepin. The overall average of deaths per million prescriptions was 30.1. The overall rate for tricyclic drugs was 34.14 (95% confidence interval 32.47 to 38.86; P < 0.001), monoamine oxidase inhibitors 13.48 (6.93 to 22.19; P < 0.001), atypical drugs 6.19 (4.04 to 8.80; P < 0.001), and selective serotonin reuptake inhibitors 2.02 (0.64 to 4.17; P < 0.001). The numbers of deaths per million prescriptions of amoxapine, dothiepin, and amitriptyline were significantly higher than expected, while nine drugs had a significantly lower number of deaths per million prescriptions than expected. Analysis of deaths per defined daily dose showed a similar pattern.
CONCLUSIONS: Safety in overdose should be considered in risk-benefit and cost-benefit considerations of antidepressants. A switch in prescribing, from drugs with a high number of deaths per million prescriptions to drugs with a low number, could reduce the numbers of deaths from overdose. Although this form of suicide prevention can be implemented easily and immediately, its introduction needs to be considered against the higher costs of some of the newer drugs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7866123      PMCID: PMC2548619          DOI: 10.1136/bmj.310.6974.221

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  21 in total

1.  Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin.

Authors:  E J Hatziandreu; R E Brown; D A Revicki; R Turner; J Martindale; S Levine; J E Siegel
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

2.  Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates.

Authors:  S A Montgomery; J Henry; G McDonald; T Dinan; M Lader; I Hindmarch; A Clare; D Nutt
Journal:  Int Clin Psychopharmacol       Date:  1994       Impact factor: 1.659

3.  Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide.

Authors:  N Freemantle; A House; F Song; J M Mason; T A Sheldon
Journal:  BMJ       Date:  1994-07-23

4.  Subcortical dementia.

Authors:  F J Dunne
Journal:  BMJ       Date:  1993-07-03

5.  High mortality by natural and unnatural causes: a 10 year follow up study of patients admitted to a poisoning treatment centre after suicide attempts.

Authors:  M Nordentoft; L Breum; L K Munck; A G Nordestgaard; A Hunding; P A Laursen Bjaeldager
Journal:  BMJ       Date:  1993-06-19

6.  What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment.

Authors:  B Jönsson; P E Bebbington
Journal:  Br J Psychiatry       Date:  1994-05       Impact factor: 9.319

7.  Suicide and fatal antidepressant poisoning.

Authors:  J A Henry; C A Antao
Journal:  Eur J Med       Date:  1992-10

8.  Antidepressant medications and the relative risk of suicide attempt and suicide.

Authors:  S Kapur; T Mieczkowski; J J Mann
Journal:  JAMA       Date:  1992 Dec 23-30       Impact factor: 56.272

9.  Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis.

Authors:  E A Workman; D D Short
Journal:  J Clin Psychiatry       Date:  1993-01       Impact factor: 4.384

10.  Use of antidepressants among people committing suicide in Sweden.

Authors:  G Isacsson; P Holmgren; D Wasserman; U Bergman
Journal:  BMJ       Date:  1994-02-19
View more
  42 in total

Review 1.  Herbal remedies: issues in licensing and economic evaluation.

Authors:  D M Ashcroft; A L Po
Journal:  Pharmacoeconomics       Date:  1999-10       Impact factor: 4.981

2.  Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data.

Authors:  Nicholas A Buckley; Peter R McManus
Journal:  BMJ       Date:  2002-12-07

3.  Toxicological findings in suicides - frequency of antidepressant and antipsychotic substances.

Authors:  Maximilian Methling; Franziska Krumbiegel; Sven Hartwig; Maria K Parr; Michael Tsokos
Journal:  Forensic Sci Med Pathol       Date:  2018-11-05       Impact factor: 2.007

4.  Do selective serotonin reuptake inhibitors cause suicide? Data seem to be incorrect.

Authors:  Alex J Mitchell
Journal:  BMJ       Date:  2005-05-14

Review 5.  Tricyclic antidepressant overdose: a review.

Authors:  G W Kerr; A C McGuffie; S Wilkie
Journal:  Emerg Med J       Date:  2001-07       Impact factor: 2.740

6.  Suicidal antidepressant overdoses: a comparative analysis by antidepressant type.

Authors:  Nicole White; Toby Litovitz; Cathleen Clancy
Journal:  J Med Toxicol       Date:  2008-12

Review 7.  Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: consensus statement.

Authors:  Hans-Jürgen Möller; David S Baldwin; Guy Goodwin; Siegfried Kasper; Ahmed Okasha; Dan J Stein; Rajiv Tandon; Marcio Versiani
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-08       Impact factor: 5.270

8.  Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data?

Authors:  N A Buckley; P R McManus
Journal:  Drug Saf       Date:  1998-05       Impact factor: 5.606

9.  Antidepressants and suicide. Study analyses were flawed.

Authors:  I Whyte; N Buckley; G Carter
Journal:  BMJ       Date:  1995-07-01

Review 10.  Escitalopram: a pharmacoeconomic review of its use in depression.

Authors:  Katherine F Croom; Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.